Indo Gulf Inds. (506945)

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at a P/B of 0.52, i.e. ₹4.94 per share versus book value of ₹9.50.
• Positive ROCE of 45.19% despite net losses suggests operational capital efficiency.
• Quarterly sales of ₹48 crore are enormous relative to a ₹5 crore market cap, implying high revenue per market rupee.
• No debt-to-equity ratio is reported, so the balance sheet does not appear heavily leveraged.

Concerns

• ROE is deeply negative at -22.89%, and the latest quarter posted a net loss of ₹4 crore.
• Sales growth is down 21.20% and profit growth is down 260.18%, indicating serious deterioration.
• Piotroski F-Score of 3/9 signals weak financial health and possible distress.
• No dividend, no promoter holding data, and insufficient disclosures reduce confidence.

AI Analysis

When I look at Indo Gulf Industries, the first thing that catches my eye is a rupee of assets selling for fifty-two paise. At ₹4.94 against a book value of ₹9.50, the stock trades at a 48% discount to stated book value. That is the Graham part: margin of safety in net asset terms. But a cheap price is not enough. The business itself is bleeding. Return on equity is -22.89%, and the latest quarter showed sales of ₹48 crore with a net loss of ₹4 crore. Sales are declining at 21.20%, and profit has turned sharply negative—down 260.18%. The Piotroski F-score of 3 out of 9 reinforces the picture of weak fundamentals. I cannot call this a great business; there is no evident moat in specialty chemicals at this scale, and the market cap of only ₹5 crore suggests limited visibility. What keeps me interested is the balance sheet angle. With no debt-to-equity figure shown and a positive ROCE of 45.19%, the underlying operations may still create value at the capital-employed level, even if net income is negative. The share price sits at its 52-week high, which is interesting—Mr. Market is beginning to notice. Still, I would not rely on growth. Sales are falling, no dividend is paid, and promoter data is unavailable. This is an asset play, not a compounder. I would only buy if I could take control or if the discount to book were much wider, because a negative-ROE business can burn the margin of safety. Watch for a return to positive quarterly profit, stabilization of sales, and any clarity on promoter holding. Until then, I would keep it small or on the shelf.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer